Healthcare / Diagnostics & ResearchTSXV
$0.06
+0.00 (+10.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-386456.00 · quality 33.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-477.1%
↓Gross Margin
44.6%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-32.9%
FCF CAGR
—
FCF margin
-169.4%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $533884.0 · net income $-1.9M · FCF $-904295.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $533884.00 | $533884.00 | $4.8M | $3.5M | $1.8M |
| Net Income | $-1.9M | $-1.9M | $-668977.00 | $-701215.00 | $-818228.00 |
| EBITDA | $-1.1M | $-1.1M | $589544.00 | $-267178.00 | $-629477.00 |
| EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Gross Margin | 44.6% | 44.6% | 39.3% | 34.5% | 25.8% |
| Operating Margin | -237.2% | -237.2% | 2.9% | -19.7% | -45.9% |
| Net Margin | -348.2% | -348.2% | -14.0% | -20.1% | -46.3% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.02 | 0.02 |
| Current Ratio | 2.11 | 2.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-904295.00 | $-904295.00 | $799268.00 | $-386456.00 | $-1.6M |
| Returns | |||||
| ROE | -477.1% | -477.1% | -34.0% | -34.9% | -41.7% |
| Valuation | |||||
| EV/EBITDA | — | — | 8.29 | — | — |
| P/B | 14.30 | 14.30 | 3.06 | 8.67 | 15.94 |
| Growth & Yield | |||||
| Revenue Growth | -88.8% | -88.8% | 37.3% | 97.1% | — |
| EPS Growth | -100.0% | -100.0% | 0.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.02
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.